194 related articles for article (PubMed ID: 36861344)
1. Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.
Roy AM; George S
Immunotherapy; 2023 Apr; 15(6):397-400. PubMed ID: 36861344
[TBL] [Abstract][Full Text] [Related]
2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
3. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
4. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
Oppel-Heuchel H; Grimm MO
Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
[TBL] [Abstract][Full Text] [Related]
5. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
7. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
[TBL] [Abstract][Full Text] [Related]
8. Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice.
Dri A; Garattini SK; Cinausero M; Macerelli M; Fanelli M; Puglisi F; Fasola G; Ermacora P
Curr Oncol; 2022 Sep; 29(10):6776-6786. PubMed ID: 36290810
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
10. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1.
Brigida M; Perricelli A; Sposato F; Spadafora MG; Pomillo A; Sisto M
Rev Recent Clin Trials; 2020; 15(4):339-346. PubMed ID: 32568023
[TBL] [Abstract][Full Text] [Related]
11. [Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity].
Villabona Lisa Villabona L; Costa Svedman F; Jovanovic B; Kaneteg B; Eberhardson M; Magin H; Ullenhag G; Blomqvist L; Helgadottir H
Lakartidningen; 2021 Nov; 118():. PubMed ID: 35080767
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy and the management of side effects.
Mahalingam P; Newsom-Davis T
Clin Med (Lond); 2023 Jan; 23(1):56-60. PubMed ID: 36697001
[TBL] [Abstract][Full Text] [Related]
13. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
15. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
18. New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
Barquín-García A; Molina-Cerrillo J; Garrido P; Garcia-Palos D; Carrato A; Alonso-Gordoa T
Eur J Intern Med; 2019 Aug; 66():1-8. PubMed ID: 31130304
[TBL] [Abstract][Full Text] [Related]
19. Side Effects and Efficacy of Immunotherapy.
Fiala O; Šorejs O; Šustr J; Fínek J
Klin Onkol; 2020; 33(1):8-10. PubMed ID: 32075381
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]